Market Closed -
Other stock markets
|
Pre-market 02:34:47 am | |||
32.25 EUR | +1.42% | 32.2 | -0.16% |
Jun. 11 | Ardian: investment in Orion Group | CF |
Jun. 10 | AXA : Receives a Buy rating from Barclays | ZD |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
- The company has a good ESG score relative to its sector, according to Refinitiv.
Strengths
- The equity is one of the most attractive in the market with regard to earnings multiple-based valuation.
- The company has attractive valuation levels with a low EV/sales ratio compared with its peers.
- This company will be of major interest to investors in search of a high dividend stock.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Life & Health Insurance
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+9.36% | 77B | B- | ||
+6.90% | 50.11B | B | ||
+4.37% | 49.08B | B+ | ||
+21.00% | 46.31B | B+ | ||
+10.85% | 41.28B | B+ | ||
+23.21% | 39.52B | B | ||
+17.12% | 33.17B | B | ||
-3.10% | 28.2B | B | ||
-9.14% | 27.14B | B- | ||
+26.56% | 26.34B | A |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- CS Stock
- Ratings AXA